News

Study 332 showed that FYCOMPA, when used as adjunctive therapy in the treatment of PGTC seizures in patients age 12 and older, reduced median percent in seizure frequency

Market surveys clearly indicate that Brazil is one of the fastest growing pharmaceutical markets globally, with its huge population of more than 200 million, an investment friendly environment,

Allergan chose to initiate this recall based on a small number of customer complaints which reported a small black particle at the time of use. This black particle,

Canada-based Portage Biotech holds 54% equity interest in Biohaven Pharmaceutical Holding Company. With the completion of FDA review, Biohaven now plans to immediately proceed with a Phase I

HLD-200 uses Ironshore’s drug delivery platform, DELEXIS, to enable nighttime dosing of these patients. The multicenter, double-blind, randomized, placebo-controlled, parallel group Phase III trial (AHEAD) is designed to

Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works by inducing stimulation and differentiation of megakaryocytes from bone marrow stem cells to increase platelet production. The

The fully randomized placebo-controlled trial, conducted by Moore Clinical Research, an independent FDA-compliant contract research organization (CRO), compares the performance of HSRx’s acne treatment product with that of

Retinitis pigmentosa leads to the progressive degeneration of rod and cone photoreceptors (cells found in the retina that sense light), resulting in severe vision loss and blindness. With

Talazoparib is currently in a Phase III trial designed to treat patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.